drugset
drugset / Trial / NCT00100880

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

NCT00100880 ↗

Phase 1 Completed 45 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors. Lenalidomide may stop the growth of CNS tumors by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.

Timeline

Start
2004-11
Primary completion
2010-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified — Oral

Indications

atypical teratoid rhabdoid tumor childhood central nervous system germ cell tumor childhood cerebellar astrocytic neoplasm childhood cerebral astrocytoma childhood choroid plexus neoplasm childhood medulloblastoma childhood oligodendroglioma craniopharyngioma ependymoblastoma grade II meningioma grade III meningioma medulloepithelioma mixed glioma pediatric infratentorial ependymoma pediatric supratentorial ependymoma pineoblastoma subependymal giant cell astrocytoma supratentorial primitive neuroectodermal tumor